Durect, Endo Form Sufentanil Patch Deal Worth Up To $45M March 15, 2005 Durect Corp. formed a commercialization agreement worth up to $45 million in up-front and milestone payments for its transdermal patch pain product with Endo Pharmaceuticals Holdings Inc. (BioWorld Today)Read More
RSS